Jochum W, Schröder S, al-Taha R, August C, Gross A J, Berger J, Padberg B C
Institute of Clinical Pathology, University of Zürich, Switzerland.
Cancer. 1996 Feb 1;77(3):514-21. doi: 10.1002/(SICI)1097-0142(19960201)77:3<514::AID-CNCR13>3.0.CO;2-7.
For a variety of human malignancies, static DNA cytophotometry and immunostaining for the Ki-67 antigen using the antibody MIB-1 have provided significant prognostic information.
Surgical specimens of 58 renal cell carcinomas (RCCs) were investigated by conventional histology, DNA cytophotometry, and MIB-1 immunostaining.
The MIB-1 indices and DNA data were found not only to be significantly correlated with various other morphologic parameters, but also to the clinical behavior of RCC. In the course of this study (median observation period: 31 months), 27% of patients died from RCC. None of these patients belonged to the group of 37 patients with RCCs exhibiting diploid or euploid DNA histograms. Lethal outcome occurred in only 16 of the 21 patients (76%) with noneuploid or aneuploid histogram tumors (P < 0.0001). According to their MIB-1 indices and upon choosing different cutoff levels, the 58 RCCs were categorized into 2 groups with either low or high proliferative activity. Using the median and the mean MIB-1 index as cutoffs, none of the patients with tumors showing low proliferative activity had died, whereas 16 of 29 patients (55%) or, respectively, 16 of 25 patients (64%) with tumors exhibiting high proliferative activity, had died from RCC (P < 0.0001).
In addition to tumor grade and stage, both a high MIB-1 index and a noneuploid or aneuploid DNA histogram of a given RCC have the potential to identify tumor patients with an impaired prognosis.
对于多种人类恶性肿瘤,静态DNA细胞光度测定法以及使用MIB - 1抗体对Ki - 67抗原进行免疫染色已提供了重要的预后信息。
对58例肾细胞癌(RCC)的手术标本进行常规组织学、DNA细胞光度测定法以及MIB - 1免疫染色研究。
发现MIB - 1指数和DNA数据不仅与各种其他形态学参数显著相关,而且与RCC的临床行为相关。在本研究过程中(中位观察期:31个月),27%的患者死于RCC。这些患者中无一属于37例显示二倍体或整倍体DNA直方图的RCC患者组。在21例具有非整倍体或异倍体直方图肿瘤的患者中,仅有16例(76%)出现致命结局(P < 0.0001)。根据其MIB - 1指数并选择不同的临界值水平,将58例RCC分为增殖活性低或高的两组。以MIB - 1指数的中位数和平均值作为临界值,增殖活性低的肿瘤患者无一死亡,而增殖活性高的肿瘤患者中,29例中有16例(55%)或25例中有16例(64%)死于RCC(P < 0.0001)。
除肿瘤分级和分期外,给定RCC的高MIB - 1指数以及非整倍体或异倍体DNA直方图均有可能识别预后不良的肿瘤患者。